Who Owns Bicycle Therapeutics Stock?
NASDAQ: BCYCHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 3.89 0.00%
Ownership breakdown
- Held by institutions
- 72.05%
- Held by insiders
- 4.47%
- Institutional holders
- 127
- Institutions 72.0%
- Insiders 4.5%
- Public and other 23.5%
Who owns Bicycle Therapeutics stock?
Institutional investors own about 72.0% of Bicycle Therapeutics's shares, spread across 127 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 4.47% of BCYC.
The largest institutional holders are Baker Bros. Advisors, LP (21.53%), FCPM III Services B.V. (6.86%) and Armistice Capital, LLC (6.72%). Together, the top 10 institutions control 56.5% of shares outstanding. In their latest filings, 3 of the top 10 institutions increased their BCYC positions and 1 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of BCYC
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Baker Bros. Advisors, LP | 10.89M | 21.53% | 0.0% |
| FCPM III Services B.V. | 3.47M | 6.86% | 0.0% |
| Armistice Capital, LLC | 3.40M | 6.72% | 0.0% |
| Long Focus Capital Management, LLC | 3.31M | 6.55% | 0.0% |
| Acadian Asset Management. LLC | 1.97M | 3.89% | 0.0% |
| Renaissance Technologies, LLC | 1.53M | 3.03% | +56.6% |
| GSK plc | 1.53M | 3.03% | 0.0% |
| Price (T.Rowe) Associates Inc | 902.15K | 1.78% | -12.3% |
| Marshall Wace LLP | 797.94K | 1.58% | +111.5% |
| Qube Research & Technologies Ltd | 775.57K | 1.53% | +151.3% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of BCYC
| Fund | Shares | % Held |
|---|---|---|
| T. Rowe Price Health Sciences Fund, Inc. | 628.42K | 1.24% |
| iShares Trust-iShares Biotechnology ETF | 278.90K | 0.55% |
| Old Westbury Funds Inc-Old Westbury Small & Mid Cap Strategies Fund | 265.97K | 0.53% |
| ETFis Series Trust I-Virtus Biotech Clinical Trials ETF | 76.74K | 0.15% |
| T. ROWE PRICE Eqy. SERIES, INC.-T. Rowe Price Health Sciences PORT. | 62.85K | 0.12% |
| ALPS ETF TRUST-ALPS Medical Breakthroughs ETF | 51.45K | 0.10% |
| SPDR INDEX SHARES Fd.S-State Street SPDR S&P Intl Small Cap ETF | 30.98K | 0.06% |
| Voya Mutual Funds-Voya Multi-Manager International Small Cap Fund | 30.05K | 0.06% |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 27.31K | 0.05% |
| John Hancock Variable Insurance Trust-Health Sciences Trust | 25.60K | 0.05% |
Frequently asked questions
Who is the largest shareholder of Bicycle Therapeutics?
Baker Bros. Advisors, LP is the largest institutional shareholder of BCYC, owning 21.53% of shares outstanding (10.89M shares) as of its latest 13F filing.
What percentage of Bicycle Therapeutics is owned by institutions?
Institutions own about 72.0% of BCYC shares and 75.4% of the public float.
How much of Bicycle Therapeutics do insiders own?
Insiders, such as officers and directors, own about 4.47% of BCYC shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.